Erythematous and purpuric plaques of the face and scalp in Sweet syndrome
Paraneoplastic pemphigus due to natural-killer/T-cell lymphoma
Recent advances in the understanding and management of MYH9 -related inherited thrombocytopenias
Preservation of fertility in females with haematological malignancy
Advances in the prognostication and management of advanced MDS in children
Guideline on the investigation, management and prevention of venous thrombosis in children*
Guideline on the management of haemophilia in the fetus and neonate*
Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9
Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia
Common genetic variation at 15q25.2 impacts on chronic lymphocytic leukaemia risk
Impaired immune function in children with Fanconi anaemia
Resistance to activated protein C is a risk factor for pregnancy-related venous thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphism
Krüppel-like Factor 4 activates HBG gene expression in primary erythroid cells
Identification of RHCE and KEL alleles in large cohorts of Afro-Caribbean and Comorian donors by multiplex SNaPshot and fragment assays: a transfusion support for sickle cell disease patients
A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction
Cytogenetic and molecular genetic characterization of the ‘high hyperdiploid’ B-cell precursor acute lymphoblastic leukaemia cell line MHH-CALL-2 reveals a near-haploid origin
Sweet syndrome in patients with Fanconi anaemia: association with extracutaneous manifestations and progression of haematological disease
Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes
Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma